Keywords
Denosumab
Metabolism
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the effectiveness of denosumab in the treatment of postmenopausal osteoporosis, focusing on bone mineral density and possible metabolic changes. Method: An integrative literature review was conducted using the PUBMED/MEDLINE, ScienceDirect, SciELO, and BVS/LILACS databases, including studies from the past 10 years. Data collection took place between December 2024 and January 2025, using the descriptors “Postmenopausal Osteoporosis,” “Metabolism,” and “Denosumab.” Results: Eight studies were included, totaling 33,505 women. The results indicate that denosumab significantly reduces the risk of osteoporotic fractures and increases bone mineral density, with reduced osteoclastic activity, evidenced by markers such as total alkaline phosphatase and osteocalcin. An increase in triglyceride levels was also observed between the third and sixth months of use, indicating the need for lipid monitoring. Cases of hypocalcemia were reported, particularly among patients with comorbidities or concomitant medication use. Final Considerations: Compared to bisphosphonates and placebo, denosumab showed good tolerability and a low incidence of serious adverse effects. It is concluded that denosumab is an effective and safe alternative for postmenopausal osteoporosis, although monitoring for metabolic changes is recommended.
References
BRASIL. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas da Osteoporose. Brasília: Ministério da Saúde; 2022. Disponível em: https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2022/20220919_pcdt_osteoporose.pdf
CRANDALL CJ, et al. Serial bone density measurement and incident fracture risk discrimination in postmenopausal women. JAMA Intern Med, 2020; 180(9): 1232–1240.
EASTELL R, et al. Advances in the treatment of osteoporosis. Lancet, 2019; 393(10169): 364–76. doi:10.1016/S0140-6736(18)32112-3
FERRARI S, et al. Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone, 2020; 134: 115268.
FOOD AND DRUG ADMINISTRATION (FDA). Approves new injectable treatment for osteoporosis for postmenopausal women. FDA; 2010. Disponível em: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm214150.htm
HAJISADEGHI H, et al. Effect of regular resistance exercise, vitamin D, and calcium supplements on the bone mineral content and density in postmenopausal model of rats. Int J Reprod Biomed, 2021; 19(1): 63–74.
HEALTH CANADA. Summary Basis of the Decision-PROLIA. 2011. Disponível em: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drugmed/sbd_smd_2011_prolia_121139-eng.pdf
INTERNATIONAL OSTEOPOROSIS FOUNDATION. Epidemiology of osteoporosis and fragility fractures [Internet]. 2025. Disponível em: https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures
KIM KJ, et al. A simple-to-use score for identifying individuals at high risk of denosumab-associated hypocalcemia in postmenopausal osteoporosis: a real-world cohort study. Calcif Tissue Int, 2020; 107(6): 567–575.
KOH JM, et al. Assessment of denosumab in Korean postmenopausal women with osteoporosis: randomized, double-blind, placebo-controlled trial with open-label extension. Yonsei Med J, 2016; 57(4): 905–914.
LAI EC, et al. Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study. Osteoporos Int, 2022; 33(5): 1155–1164.
LASCO A, et al. Inhibition of RANKL denosumab and insulin resistance in postmenopausal women with osteoporosis. Calcif Tissue Int, 2016; 98(2): 123–8.
MORGAN KP, et al. Denosumab for first-line treatment of hypercalcemia associated with malignancy: retrospective analysis. J Hematol Oncol Pharm, 2021; 11(3): 121–126.
NORTH AMERICAN MENOPAUSE SOCIETY. Menopause practice: a clinical guide. 6th ed. 2022.
PAGE MJ, et al. A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas. Epidemiol Serv Saude, 2022; 31(2).
PAPAPOULOS S, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res, 2012; 27(3): 694–701. doi:10.1002/jbmr.1479.
PAPAPOULOS S, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int, 2015; 26(12): 2773–83.
ROSEN CJ. The epidemiology and pathogenesis of osteoporosis. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2020.
RŮŽIČKOVÁ O, et al. Real-world management of postmenopausal osteoporosis women treated with denosumab: a prospective observational study in the Czech Republic and Slovakia. Adv Ther, 2018; 35(10): 1713–28.
SÁNCHEZ A, et al. Effect of denosumab on bone mineral density and bone turnover markers among postmenopausal women with osteoporosis. J Osteoporos, 2016; 2016: 8738959.
SÃO PAULO STATE DEPARTMENT OF HEALTH. PTC Denosumab. São Paulo: São Paulo State Department of Health; 2015. Disponível em: https://www.saude.sp.gov.br/resources/instituto-de-saude/homepage/pdfs/ptc_denosumabe_final_comcapa.pdf
TSVETOV G, et al. Denosumab-induced hypocalcemia in patients with osteoporosis. Osteoporos Int, 2020; 31(4): 655–665.
WU CH, et al. Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. Bone Rep, 2020.